News PRESENTATION: ADAXION Therapeutics Presents on the Engineering of Hypoimmunogenic Biotherapeutics through a Novel Bioconjugate Platform at the Keystone Symposia, Antibodies as Drugs: Engineering and Computational Tools Enabling Clinical AdvancesFebruary 2, 2026 POSTER: ADAXION Therapeutics Presents on the Design of a Deimmunized EndoS for IgG-Mediated Diseases Using the ADAx Platform at PepTalk 2026January 20, 2026 PRESENTATION: ADAXION Therapeutics Highlights Platform Technology, ADAx, a Novel Platform for Overcoming Immunogenicity in Biologics at Antibody Engineering & Therapeutics US 2026December 16, 2025 POSTER: ADAXION Therapeutics Presents on ADX-001, a Deimmunized, Half-life Extended Anti-TNFα/IL-23p19 Bifunctional Antibody for Inflammatory Diseases at Antibody Engineering & Therapeutics US 2026December 16, 2025
